At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,400 enrolled
Drug / intervention
percutaneous coronary intervention +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype in Prediction of Coronary Events in General Population
Russian Cardiology Research and Production Center·interventional·Posted Aug 5, 2015·Updated Aug 5, 2015
In Brief
A clinical study evaluating percutaneous coronary intervention and coronary artery bypass grafting for Coronary Disease and Cardiovascular Diseases. Completed, enrolled 1,400 participants.
Detailed Summary
The purpose of this study is to explore the role of lipoprotein(a) and apolipoprotein(a) phenotype in fatal and non-fatal cardiovascular disease (CVD) events risk in coronary disease patients divided on the basis of management strategy - medical, endovascular or open cardiac surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Cardiovascular Diseases
Countries--
Collaborators--
Timeline
N/ACompletedFinished
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1993
Primary CompletionSep 2006
Study CompletionJan 2014
First PostedAug 2015
TodayJul 2026
First PostedAug 5, 2015
Enrollment StartJan 1, 1993
Primary CompletionSep 1, 2006
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 13.7 yearsPosted 10.9 years ago
Interventions
percutaneous coronary interventionprocedure
elective percutaneous coronary balloon angioplasty and/or stenting
coronary artery bypass graftingprocedure
elective surgical myocardial revascularisation